Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CNS Pharmaceuticals, Inc.CNSP · Entity 8048 | Director | November 17, 2025 | November 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CNS Pharmaceuticals, Inc.
Report date November 17, 2025 · Filed November 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $12.48 · Expires 2035-11-17 | Direct | 1,517 |
Reported balance
After 2025-11-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-17 · Grant · Acquired 1,517 · Balance 1,517 F1: The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date"). F3: Issued in connection with the reporting person's employment with the Company. F2: The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date").
F2: The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date.
F3: Issued in connection with the reporting person's employment with the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 17, 2025 Filed Nov 19, 2025 22:00 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 1,517 | $0.00 Strike: $12.48 | $0.00 |
DisclosureSEC source: 0001683168-25-008561 · ownership.xml · derivative · entry 1 Gumulka Jerzy · CIK 0001793252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,517 Underlying: Common Stock · 1,517 shares Expires 2035-11-17 F1 · date: The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date"). F3 · price: Issued in connection with the reporting person's employment with the Company. F2 · derivative.exercise_date: The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 01:52 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantRestricted Stock Units · Derivative | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-24-002288 · ownership.xml · derivative · entry 2 Gumulka Jerzy · CIK 0001793252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,594 Underlying: Common Stock · 17,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company common stock. F2 · price: The awards were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date. F1 · derivative.expiration_date: The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 01:52 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 17,500 | Not disclosed Strike: $0.26 | Not disclosed |
DisclosureSEC source: 0001683168-24-002288 · ownership.xml · derivative · entry 1 Gumulka Jerzy · CIK 0001793252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,594 Underlying: Common Stock · 17,500 shares Expires 2034-04-08 F2 · price: The awards were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 15:28 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantSeries B Warrant to purchase common stock · Derivative | 33,333 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001683168-24-000708 · ownership.xml · derivative · entry 3 Gumulka Jerzy · CIK 0001793252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,094 Underlying: Common Stock · 33,333 shares Expires 2025-10-01 F1 · price: The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 15:28 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantSeries A Warrant to purchase common stock · Derivative | 33,333 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001683168-24-000708 · ownership.xml · derivative · entry 2 Gumulka Jerzy · CIK 0001793252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,761 Underlying: Common Stock · 33,333 shares Expires 2029-02-01 F1 · price: The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 15:28 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | PurchaseCommon stock | 33,333 | $0.30 | $9,999.90 |
DisclosureSEC source: 0001683168-24-000708 · ownership.xml · nonDerivative · entry 1 Gumulka Jerzy · CIK 0001793252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,006 F1 · price: The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024. Read SEC document |
| September 21, 2023 Filed Sep 25, 2023 22:26 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 68,961 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0001683168-23-006684 · ownership.xml · derivative · entry 1 Gumulka Jerzy · CIK 0001793252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,914 Underlying: Common Stock · 68,961 shares Expires 2033-09-22 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| September 21, 2023 Filed Oct 12, 2023 22:01 UTC Amendment | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 39,475 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0001683168-23-007111 · ownership.xml · derivative · entry 1 Gumulka Jerzy · CIK 0001793252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,428 Underlying: Common Stock · 39,475 shares Expires 2033-09-22 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| April 19, 2023 Filed Apr 21, 2023 11:58 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | PurchaseCommon Stock | 2,500 | $1.70 | $4,250.00 |
DisclosureSEC source: 0001683168-23-002562 · ownership.xml · nonDerivative · entry 1 Gumulka Jerzy · CIK 0001793252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,673 Read SEC document |
| April 10, 2023 Filed Apr 17, 2023 12:17 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | PurchaseCommon Stock | 7,173 | $0.74 | $5,308.02 |
DisclosureSEC source: 0001683168-23-002424 · ownership.xml · nonDerivative · entry 1 Gumulka Jerzy · CIK 0001793252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,173 Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 21:00 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 32,000 | Not disclosed Strike: $1.80 | Not disclosed |
DisclosureSEC source: 0001683168-21-003000 · ownership.xml · derivative · entry 1 Gumulka Jerzy · CIK 0001793252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,559 Underlying: Common Stock · 32,000 shares Expires 2031-07-15 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on the earlier of the one-year anniversary of the date hereof or the date of the 2022 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 21:23 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 46,559 | Not disclosed Strike: $2.47 | Not disclosed |
DisclosureSEC source: 0001683168-20-001967 · ownership.xml · derivative · entry 1 Gumulka Jerzy · CIK 0001793252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,559 Underlying: Common Stock · 46,559 shares Expires 2030-06-12 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on the earlier of the one-year anniversary of the issuance date or the date of the 2021 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.